Insomnia and Esketamine Add-On Therapy to Antidepressant Therapy in Patients with Treatment-Resistant Depression-A Pilot Study.
Pharmaceuticals (Basel, Switzerland) July 19, 2025 Daniel Szawarnoga, Joanna Fojcik, Michał Górski et al. 1 citation
Insomnia is common among people with drug-resistant depression and can undermine treatment and quality of life. In a comparison of 50 patients, those taking esketamine combined with other antidepressants had less insomnia than those taking other antidepressants alone. Longer use and higher doses of esketamine were associated with further reductions in insomnia. Esketamine produces a rapid improvement in sleep quality, offering an advantage over standard antidepressants for this population.